Nociscan Solution & Market Opportunity - Nociscan leverages MR Spectroscopy and Augmented Intelligence for patients with pain of spinal origin [9] - Nociscan labels each disc as painful or pain free based upon a biochemical signal and correlation with provocative discography, leading to lower cost, better outcomes, and higher value care [14] - The U S low back & neck pain market represents an ultimate market of $135 billion [17] - The U S lumbar spine market (fusion & non-fusion surgery plus presurgical care) represents an expansion market of $40 billion [16] - The U S lumbar fusion & disc replacement market represents an actionable market of $10 billion [17] Foundational Science & Technology - Elevated Lactate is associated with Nociceptor Activation, Excessive Cellular Demand, Cell Death and Reduced PG Synthesis [23] - Spectroscopy analyzes the chemical composition of tissue, transforming raw spectral data into clear biomarkers [26] - Nociscan uses six ratios for each disc, with pain markers in the numerator and structural integrity markers in the denominator, leveraging AI for major advancements [30, 33] Clinical and Economic Evidence - MRS (NOCI+/–) compared to PD (P/NP) with an accuracy of 87%, sensitivity of 100%, and specificity of 80% [47] - The positive predictive value (PPV) in herniated discs, and negative predictive value (NPV) in non-herniated discs, were 100% [47] - MRS with the Nociscan diagnostic algorithm demonstrates cost-effectiveness dominance over PD for identifying CLBP surgical candidates, with annualized US savings estimated between $283 million and $441 million [51, 53] Intellectual Property & Availability - Aclarion has 23 issued U S Patents and 13 Pending Patent Applications [39, 38] - Over 1,100 Commercial Nociscans have been performed [97]